NXV01 / neoX Biotech - LARVOL DELTA

Discovery and characterization of NXV01c, an EGFR×cMET bispecific nanobody drug conjugate with potent anti-tumor activity (AACR 2024) - "To examine stability of conjugation, NXV01C was incubated in human plasma (37℃) for 14 days, the maximum free drug release rate (by LC/MS/MS) is 0.68%, which is much lower than that of DS8201. EGFR×cMET bispecific nanobody drug conjugate NXV01c has favorable drug-like properties and demonstrated superior anti-tumor effect in vitro and in vivo. The results suggest NXV01C can be an effective solution for EGFR/cMET bearing tumors commonly found in diverse malignancies."

Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Liver Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR